The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies.

Drugs R D · 2026 · PMC13076746 · PMID 41903096

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, in moderate hepatic impairment group, C max showed a trend of being 18% lower, while overall exposure was higher (AUC 0–tz by ~ 29% and AUC 0–∞ by ~ 57%) compared with matched participants.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.